AngioScore completes $30 million financing to fund new catheter

By Elaine Rigoli

Tampa, Fla., April 11 - AngioScore, Inc. announced Tuesday the successful completion of a $30 million private equity financing.

The series D round was led by Telegraph Hill Partners. QuestMark Partners LP also participated as a new institutional investor in this round. The company's existing institutional investors, all of whom participated in this round, include Psilos Group Management, UV Partners, California Technology Ventures and Innomed Ventures.

The funds from this financing will be used primarily to expand the company's global manufacturing effort and launch the AngioSculpt in the U.S. market, officials said.

The company has received 510(k) clearance from the Food and Drug Administration to market the AngioSculpt for balloon dilatation of lesions in infra-popliteal arteries (peripheral artery disease below the knee), and has submitted a pre-market application for the AngioSculpt for the treatment of coronary artery disease.

AngioScore, a developer of angioplasty catheters for use in the treatment of coronary and peripheral artery disease, is located in Fremont, Calif.

Issuer: AngioScore, Inc.

Issue: Series D financing

Amount: $30 million

Investors: Telegraph Hill Partners (lead), QuestMark Partners LP, Psilos Group Management, UV Partners, California Technology Ventures, Innomed Ventures

Announcement date: April 11

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.